POLIO
MCID: PLM031
MIFTS: 59

Poliomyelitis (POLIO)

Categories: Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 12 76 53 59 44 15 73
Infantile Paralysis 53 73
Polio 53 55

Characteristics:

Orphanet epidemiological data:

59
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4953
ICD10 33 A80 A80.9
ICD9CM 35 045 045.9
MeSH 44 D011051
NCIt 50 C35550
SNOMED-CT 68 54839009
Orphanet 59 ORPHA2912
ICD10 via Orphanet 34 A80.4 A80.2 A80.3 more
MESH via Orphanet 45 D011051
UMLS via Orphanet 74 C0032371

Summaries for Poliomyelitis

NIH Rare Diseases : 53 Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. Treatment is aimed at controlling symptoms while the infection runs its course. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced. The prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected.

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to paralytic poliomyelitis and tetanus. An important gene associated with Poliomyelitis is PVR (Poliovirus Receptor), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Phenol and Neomycin have been mentioned in the context of this disorder. Affiliated tissues include bone, spinal cord and brain, and related phenotypes are hematopoietic system and growth/size/body region

Disease Ontology : 12 A viral infectious disease that results in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 76 Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 358)
# Related Disease Score Top Affiliating Genes
1 paralytic poliomyelitis 33.6 ARHGEF1 DPT PVR
2 tetanus 31.0 IFNG IL10 IL4
3 aseptic meningitis 30.6 IFNG IL10 TNF
4 meningitis 30.5 FCGR2A IFNG IL10 TNF
5 viral infectious disease 30.4 IFNG IL10 IL4 TNF
6 rubella 30.3 IL10 IL4 TNF
7 human immunodeficiency virus infectious disease 30.2 IFNG IL10 TNF
8 behcet syndrome 30.1 IFNG IL10 TNF
9 transient hypogammaglobulinemia 30.0 IL10 TNF
10 acquired immunodeficiency syndrome 30.0 IFNG IL10 TNF
11 osteomyelitis 30.0 IFNG IL10 TNF
12 conjunctivitis 29.9 ICAM1 IFNG IL4
13 reactive arthritis 29.8 IFNG IL10 TNF
14 gastroenteritis 29.8 IL10 IL4 TNF
15 hepatitis a 29.8 IFNG IL10 TNF
16 penicillin allergy 29.8 IFNG IL10 IL4
17 neuritis 29.7 IFNG IL4 TNF
18 mouth disease 29.7 IFNG IL10 TNF
19 hemophagocytic lymphohistiocytosis 29.7 IFNG IL10 TNF
20 multiple sclerosis 29.7 ICAM1 IFNG IL10 IL4 TNF
21 leprosy 3 29.7 IFNG IL10 IL4 TNF
22 chlamydia 29.6 IFNG IL10 IL4 TNF
23 schistosomiasis 29.6 IFNG IL10 IL4 TNF
24 myasthenia gravis 29.6 IFNG IL10 IL4 TNF
25 lichen planus 29.5 ICAM1 IFNG IL4 TNF
26 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.5 BTK IFNG IL10 IL4
27 common variable immunodeficiency 29.3 BTK IFNG IL10 IL4 TNF
28 nonparalytic poliomyelitis 12.6
29 bulbar polio 12.0
30 poliomyelitis in patients with immunodeficiencies deemed at risk 12.0
31 acute flaccid myelitis 11.7
32 postpoliomyelitis syndrome 11.6
33 motor neuron disease 11.4
34 spastic diplegia 11.1
35 spinal cord disease 11.0
36 foot drop 11.0
37 spinal polio 11.0
38 bulbospinal polio 11.0
39 diphtheria 10.6
40 pertussis 10.6
41 encephalitis 10.3
42 haemophilus influenzae 10.3
43 nonalcoholic steatohepatitis 10.3 LEP TNF
44 nontuberculous mycobacterial lung disease 10.3 LEP TNF
45 trachoma 10.3 IL10 TNF
46 mucocutaneous leishmaniasis 10.3 IL10 TNF
47 hepatitis 10.3
48 measles 10.3
49 crohn's colitis 10.3 IFNG TNF
50 meconium aspiration syndrome 10.3 IFNG TNF

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

MGI Mouse Phenotypes related to Poliomyelitis:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.16 ARHGEF1 BTK DLG1 FCGR2A ICAM1 IFNG
2 growth/size/body region MP:0005378 10.13 BTK DLG1 DPT ICAM1 IFNG IL10
3 immune system MP:0005387 10.13 ARHGEF1 BTK DLG1 FCGR2A ICAM1 IFNG
4 digestive/alimentary MP:0005381 10.11 BTK DLG1 ICAM1 IFNG IL10 IL4
5 mortality/aging MP:0010768 10.07 ARHGEF1 BTK DLG1 FCGR2A ICAM1 IFNG
6 endocrine/exocrine gland MP:0005379 10.04 DLG1 ICAM1 IFNG IL10 IL4 LEP
7 integument MP:0010771 10.01 BTK DPT ICAM1 IFNG IL10 IL4
8 muscle MP:0005369 9.87 ARHGEF1 DLG1 ICAM1 IFNG IL10 LEP
9 neoplasm MP:0002006 9.73 BTK ICAM1 IFNG IL10 LEP TNF
10 respiratory system MP:0005388 9.63 DLG1 IFNG IL10 IL4 LEP TNF
11 skeleton MP:0005390 9.5 DLG1 FCGR2A IFNG IL10 IL4 LEP
12 vision/eye MP:0005391 9.23 DLG1 DPT ICAM1 IFNG IL10 IL4

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenol Approved, Experimental Phase 4 108-95-2 996
2
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
3
Zinc sulfate Approved, Investigational Phase 4,Not Applicable 7733-02-0
4
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6
5
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 62-33-9, 60-00-4 6049
6
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
7
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
8
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
9
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
10
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 11103-57-4, 68-26-8 445354
11
BCG vaccine Investigational Phase 4,Phase 2,Not Applicable
12 Antibodies, Blocking Phase 4
13 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Adjuvants, Immunologic Phase 4,Phase 1,Phase 2,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
21 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
22 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 1,Phase 2
23 Antioxidants Phase 4,Phase 2,Phase 3,Not Applicable
24 retinol Phase 4,Phase 2,Phase 3,Not Applicable
25 Retinol palmitate Phase 4,Phase 2,Phase 3,Not Applicable
26 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
27 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
28 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Polymyxin B Phase 4
30 Polymyxins Phase 4
31 Zinc Supplement Phase 4,Not Applicable
32 Acidophilus Phase 4
33 PENTA Phase 4,Phase 3,Phase 2,Not Applicable
34 Anticoagulants Phase 4,Phase 3,Phase 2
35 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
36 Calcium, Dietary Phase 4,Phase 3,Phase 2
37 Iron Chelating Agents Phase 4,Phase 3,Phase 2
38 Chelating Agents Phase 4,Phase 3,Phase 2
39 Antidotes Phase 4,Phase 3,Phase 2
40 Analgesics Phase 4,Phase 3,Phase 2
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
43 Cyclooxygenase Inhibitors Phase 4,Phase 2
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
45 Antirheumatic Agents Phase 4,Phase 2
46 Antipyretics Phase 4,Phase 3
47 Anti-Inflammatory Agents Phase 4,Phase 2
48
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 58-14-0 4993
49
leucovorin Approved Phase 2, Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
50
Sulfadoxine Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 2447-57-6 17134

Interventional clinical trials:

(show top 50) (show all 365)
# Name Status NCT ID Phase Drugs
1 Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Unknown status NCT01841671 Phase 4
2 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
3 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Unknown status NCT02408926 Phase 4
4 Influence of BCG on TDaP-IPV Vaccination Unknown status NCT02771782 Phase 4
5 Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
6 A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China Completed NCT01278433 Phase 4
7 Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine Completed NCT01475539 Phase 4
8 A Study of the Safety of IMOVAX Polio™ in China Completed NCT01244464 Phase 4
9 A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age Completed NCT02580201 Phase 4
10 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
11 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
12 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
13 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
14 A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
15 A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children Completed NCT02521974 Phase 4
16 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines Completed NCT01616693 Phase 4
17 Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine Completed NCT01831050 Phase 4
18 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
19 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
20 Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules Completed NCT02412514 Phase 4
21 Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine Completed NCT02643368 Phase 4
22 Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia Completed NCT01094171 Phase 4
23 IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi. Completed NCT01695798 Phase 4
24 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
25 Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study Completed NCT02847026 Phase 4
26 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Completed NCT03147560 Phase 4
27 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
28 Inactivated Influenza Vaccine Effectiveness in Tropical Africa Completed NCT00893906 Phase 4
29 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
30 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
31 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
32 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
33 Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV Completed NCT03310073 Phase 4
34 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
35 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
36 Poliovirus Vaccine Trial in Bangladesh Completed NCT01633216 Phase 4
37 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
38 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed NCT00325156 Phase 4
39 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
40 Different Doses of Vitamin A and Childhood Morbidity and Mortality Completed NCT00168584 Phase 4 Vitamin A
41 Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Completed NCT01457547 Phase 4
42 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
43 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
44 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed NCT00753649 Phase 4
45 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
46 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
47 A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
48 Trial of Two Strains of BCG Completed NCT02447536 Phase 4
49 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed NCT01392378 Phase 4 Paracetamol;Ibuprofen;Paracetamol;Ibuprofen
50 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

MalaCards organs/tissues related to Poliomyelitis:

41
Bone, Spinal Cord, Brain, Lung, Tonsil, T Cells, B Cells

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 1595)
# Title Authors Year
1
Evaluation of the genetic stability of Sabin strains and the consistency of inactivated poliomyelitis vaccine made from Sabin strains using direct deep-sequencing. ( 30467062 )
2019
2
Post-Polio Syndrome and the Late Effects of Poliomyelitis: Part 2. Treatment, Management and Prognosis. ( 29752826 )
2018
3
Total Hip Arthroplasty for Patients with Residual Poliomyelitis at a Mean Eight Years of Follow-up. ( 29674772 )
2018
4
Total hip arthroplasty in patients affected by poliomyelitis. ( 29855245 )
2018
5
Total Hip Arthroplasty for Patients with Residual Poliomyelitis at a Mean Eight Years of Follow-up. ( 29463934 )
2018
6
Technical aspects and complications in the surgical treatment of poliomyelitis-affected lower limb fractures. ( 29605559 )
2018
7
Post-Polio Syndrome and the Late Effects of Poliomyelitis: Part 1. Pathogenesis, Biomechanical Considerations, Diagnosis, and Investigations. ( 29752819 )
2018
8
Vaccine-associated paralytic poliomyelitis in a patient with acute lymphocytic leukemia. ( 29322435 )
2018
9
Good practices and challenges in addressing poliomyelitis and measles in the European Union. ( 29659793 )
2018
10
Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis. ( 29925653 )
2018
11
A Two-Stage Foot Repair in a 55-Year-Old Man with Poliomyelitis. ( 29547029 )
2018
12
Preparedness and response against diseases with epidemic potential in the European Union: a qualitative case study of Middle East Respiratory Syndrome (MERS) and poliomyelitis in five member states. ( 29976185 )
2018
13
Progress Toward Poliomyelitis Eradication - Nigeria, January-December 2017. ( 29494568 )
2018
14
Recipient vaccine-associated paralytic poliomyelitis in China, 2010-2015. ( 29395524 )
2018
15
Progress towards poliomyelitis eradication: Nigeria, Januarya89December 2017. ( 29498497 )
2018
16
On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine. ( 29605427 )
2018
17
Vaccine-associated paralytic poliomyelitis in the Russian Federation in 1998-2014. ( 30201507 )
2018
18
Pediatric HIV Infection and Decreased Prevalence of OPV Point Mutations Linked to Vaccine-associated Paralytic Poliomyelitis. ( 30376083 )
2018
19
Outcome of total knee arthroplasty in patients with poliomyelitis: A systematic review. ( 30034816 )
2018
20
Progress Toward Poliomyelitis Eradication - Afghanistan, January 2017-May 2018. ( 30070983 )
2018
21
Childhood Limb Poliomyelitis as a Suspected Etiology for a Contra-Lateral Femoral Arteriomegaly and Aneurysm Formation. ( 30109799 )
2018
22
Estimation of the Direct Cost of Poliomyelitis Rehabilitation Treatment to Pakistani Patients: A 53-Year Retrospective Study. ( 30128833 )
2018
23
Poliomyelitis era in Trinidad from 1940 to 1972 and beyond: Implications for effective global health governance for its eradication. ( 30234035 )
2018
24
Seroprevalence of Poliomyelitis Antibodies Among Children Aged 1 to 4 Years Old and Factors Associated With Poliovirus Susceptibility; Mexican Health and Nutrition Survey, 2012. ( 30376082 )
2018
25
Progress Toward Poliomyelitis Eradication - Pakistan, January 2017-September 2018. ( 30408024 )
2018
26
For how long do denervated muscles in children retain the ability to regenerate?: Restoration of elbow flexion and shoulder function by partial nerve transfer in a child with long-standing poliomyelitis-like paralysis. ( 30424927 )
2018
27
Radiographic and Clinical Outcomes of Surgical Correction of Poliomyelitis-Related Spinal Deformities: A Comparison Among Three Types of Pelvic Instrumentations. ( 30439526 )
2018
28
The Contribution of Poliomyelitis to President Roosevelt's Heart Failure. A Lesson on the Importance of Vaccinations for Cardiovascular Prevention. ( 30456727 )
2018
29
An ethical appraisal of the choice of vaccines against Poliomyelitis. ( 30473498 )
2018
30
Poliomyelitis. ( 30482325 )
2018
31
Poliomyelitis eradication a89 the review of notifications from the years 2010-2016 sent to National IHR Focal Point ( 28654739 )
2017
32
Progress towards poliomyelitis eradication: Afghanistan, January 2016a89June 2017. ( 28819963 )
2017
33
The push to eradicate poliomyelitis in the Eastern Mediterranean Region. ( 29178113 )
2017
34
A case-control study on the association of pulse oral poliomyelitis vaccination and Gianotti-Crosti syndrome. ( 27943306 )
2017
35
Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016. ( 29240729 )
2017
36
Progress Toward Poliomyelitis Eradication - Pakistan, January 2016-September 2017. ( 29166363 )
2017
37
Vaccine Associated Paralytic Poliomyelitis Unmasking Common Variable Immunodeficiency. ( 28361789 )
2017
38
Negative or positive? The iron lung and poliomyelitis-Zurich, 1951. ( 28675796 )
2017
39
Knowledge assessment regarding poliomyelitis among the caregivers of children who received oral polio vaccine reveals lack of awareness of the vaccine vial monitor (VVM): Implications extending beyond polio eradication. ( 28121284 )
2017
40
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial. ( 28362135 )
2017
41
Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis. ( 28604777 )
2017
42
Understanding the Dynamics of Poliomyelitis Spread in Pakistan. ( 28845415 )
2017
43
'A matter of commonsense': the Coventry poliomyelitis epidemic 1957 and the British public. ( 29118656 )
2017
44
Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization. ( 28057194 )
2017
45
A systematic review of the worldwide prevalence of survivors of poliomyelitis reported in 31 studies. ( 28694346 )
2017
46
175 Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2017. ( 28387112 )
2017
47
Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis. ( 28356537 )
2017
48
Acute segmental poliomyelitis-like flaccid paralysis in an adult in the UK, associated with enterovirus D68. ( 28626021 )
2017
49
Assessment of energy expenditure in individuals with post-poliomyelitis syndrome. ( 28355321 )
2017
50
Epidemiological Surveillance of Poliomyelitis During the Military and Political Conflict in the Central African Republic, 2013 and 2014. ( 28480271 )
2017

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 BTK FCGR2A FCGR3A ICAM1 IFNG IL10
2
Show member pathways
13.42 ARHGEF1 BTK ICAM1 IFNG IL10 IL4
3
Show member pathways
12.78 ICAM1 IFNG IL10 IL4 TNF
4
Show member pathways
12.55 BTK IFNG IL10 IL4 TNF
5
Show member pathways
12.51 IFNG IL10 IL4 TNF
6 12.45 BTK IFNG IL10 IL4 PVR TNF
7
Show member pathways
12.43 FCGR3A ICAM1 IFNG IL4 TNF
8
Show member pathways
12.35 DLG1 IFNG IL10 IL4 TNF
9
Show member pathways
12.32 IFNG IL10 IL4 LEP
10
Show member pathways
12.25 ICAM1 IFNG IL4 TNF
11
Show member pathways
12.18 IFNG IL10 IL4 TNF
12 12.17 FCGR2A FCGR3A IFNG IL10 TNF
13
Show member pathways
12.09 IFNG IL4 TNF
14 12.01 ICAM1 IFNG TNF
15
Show member pathways
12 BTK ICAM1 IFNG IL10 IL4
16 11.99 FCGR3A ICAM1 PVR
17
Show member pathways
11.97 IFNG IL10 TNF
18 11.95 ARHGEF1 BTK FCGR2A
19 11.94 BTK FCGR2A FCGR3A IFNG TNF
20 11.93 ICAM1 IL10 IL4 TNF
21
Show member pathways
11.9 FCGR2A FCGR3A IFNG IL4 TNF
22
Show member pathways
11.9 FCGR2A FCGR3A IFNG IL10 IL4 TNF
23 11.82 IFNG IL10 TNF
24 11.82 BTK ICAM1 TNF
25 11.79 ICAM1 IFNG TNF
26 11.78 FCGR2A IFNG IL10 IL4 TNF
27 11.74 ICAM1 IFNG IL4
28 11.74 IFNG IL10 IL4 TNF
29
Show member pathways
11.69 IFNG IL4 TNF
30 11.68 IFNG IL10 TNF
31
Show member pathways
11.6 ICAM1 IFNG TNF
32 11.56 FCGR2A FCGR3A ICAM1 IL10
33 11.51 FCGR2A ICAM1 IFNG IL4 LEP TNF
34 11.49 ICAM1 IL10 IL4 TNF
35 11.47 ICAM1 IFNG IL10 TNF
36 11.44 IFNG IL10 IL4
37 11.27 IFNG IL4 TNF
38 11.21 ICAM1 IFNG IL10 TNF
39 11.17 IFNG IL10 IL4
40 11.14 BTK IL10 IL4 TNF
41 11.1 ICAM1 IFNG
42 11.04 LEP TNF
43 11.02 IFNG IL10 IL4 TNF
44 10.95 FCGR2A FCGR3A IFNG IL10 IL4 TNF
45 10.93 ARHGEF1 BTK IL10 IL4 TNF
46 10.88 ICAM1 TNF

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 DPT IFNG IL10 IL4 LEP PVR
2 membrane raft GO:0045121 9.26 BTK DLG1 ICAM1 TNF
3 extracellular space GO:0005615 9.23 DPT ICAM1 IFNG IL10 IL4 LEP

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.9 ICAM1 IL10 IL4 TNF
2 immune response GO:0006955 9.89 FCGR3A IFNG IL10 IL4 TNF
3 regulation of signaling receptor activity GO:0010469 9.85 IFNG IL10 IL4 LEP TNF
4 cellular response to lipopolysaccharide GO:0071222 9.84 ICAM1 IL10 TNF
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.82 BTK ICAM1 TNF
6 regulation of immune response GO:0050776 9.81 FCGR3A ICAM1 IL4 PVR
7 response to organic substance GO:0010033 9.78 BTK IL10 TNF
8 response to insulin GO:0032868 9.75 ICAM1 IL10 LEP
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 IFNG IL4 LEP
10 regulation of insulin secretion GO:0050796 9.72 IFNG LEP TNF
11 cortical actin cytoskeleton organization GO:0030866 9.66 DLG1 TNF
12 positive regulation of protein complex assembly GO:0031334 9.65 IFNG TNF
13 protein import into nucleus, translocation GO:0000060 9.65 IFNG TNF
14 positive regulation of protein localization to plasma membrane GO:1903078 9.65 DLG1 IFNG TNF
15 positive regulation of osteoclast differentiation GO:0045672 9.64 IFNG TNF
16 leukocyte tethering or rolling GO:0050901 9.64 LEP TNF
17 negative regulation of B cell proliferation GO:0030889 9.63 BTK IL10
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 IFNG TNF
19 negative regulation of glucose import GO:0046325 9.62 LEP TNF
20 negative regulation of growth of symbiont in host GO:0044130 9.62 IL10 TNF
21 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL10 TNF
22 negative regulation of lipid storage GO:0010888 9.59 LEP TNF
23 endothelial cell apoptotic process GO:0072577 9.58 IL10 TNF
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.56 IL10 IL4
25 negative regulation of cytokine secretion involved in immune response GO:0002740 9.54 IL10 TNF
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.54 ICAM1 IFNG TNF
27 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.52 ICAM1 TNF
28 regulation of isotype switching GO:0045191 9.43 IL10 IL4
29 type 2 immune response GO:0042092 9.4 IL10 IL4
30 negative regulation of endothelial cell apoptotic process GO:2000352 9.33 ICAM1 IL10 IL4
31 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IFNG TNF
32 receptor biosynthetic process GO:0032800 9.26 IL10 TNF
33 negative regulation of mitotic cell cycle GO:0045930 9.13 DLG1 IL10 TNF
34 positive regulation of vitamin D biosynthetic process GO:0060557 8.62 IFNG TNF

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 8.96 FCGR2A FCGR3A
2 cytokine activity GO:0005125 8.92 IFNG IL10 IL4 TNF

Sources for Poliomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....